)
)
)
KiHealth is a precision diagnostics company redefining how chronic and metabolic diseases are detected, managed, and prevented. Using proprietary molecular assays and AI-driven analytics, KiHealth identifies disease risk years before symptoms appear, enabling earlier intervention and improved outcomes. The company’s flagship platform measures early beta-cell loss, the first biological signal of insulin resistance and metabolic dysfunction, allowing clinicians and biopharma partners to detect, monitor, and stratify patients at the earliest stages. Built on years of translational research, KiHealth’s portfolio extends beyond diabetes to emerging assays for pancreatic cancer risk, Alzheimer’s disease, and systemic inflammation. Partnering with leading health systems and biopharma, KiHealth is establishing early detection as the new standard of care and creating a unified platform for proactive, personalized disease prevention.
Year Founded
2023
Next catalyst (value inflection) update
We are submitting first product to the FDA in Q1 and will have data read out on our second indication.
Expected time of next catalyst update
Q1 2026
City
Saint Augustine
Country
United States
Company CEO or top company official
Jennifer Anderson
Development Phase of Primary Product
NDA Preparation/In Review
Lead Product in Development
Beta Cell Test
Therapeutic Area
Diagnostics
Website
https://www.kihealth.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
